Stock LBPH LONGBOARD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Real-time Estimate Cboe BZX
Other stock markets
 16:09:56 13/05/2024 BST 		5-day change 1st Jan Change
20.37 USD +1.24% Intraday chart for Longboard Pharmaceuticals, Inc. -1.00% +238.23%
05-03 Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating MT
05-02 Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies
CI
Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers
CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies
CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers
CI
LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement
CI
LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
LONGBOARD PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LBPH Stock
  4. News Longboard Pharmaceuticals, Inc.
  5. Highlights